AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9833745
Drug: Mexiletine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexiletine (600 mg/day)
Trial: 30895903
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone 200 mg nocte
Trial: 25042759
Drug: Group Drug
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Drug Counseling (GDC), n=48
Trial: 21162959
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (H and G)
Trial: 15572657
Drug: CAA supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAA supplements (15 g of essential amino acids and 30 g of carbohydrate)
Trial: 11736858
Drug: (+)-chlorpheniramine 2
RxNorm normalized name: chlorpheniramine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (+)-chlorpheniramine 2 mg
Trial: 2142968
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate and ethinylestradiol (2 mg cyproterone acetate + 0.035 mg ethinyl‐estradiol days 1‐21, +10 mg cyproterone acetate days 1‐15) (n = 15)
Trial: 2142968
Drug: Dexamethasone (0.25‐0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.25‐0.5 mg daily at 10 pm) (n = 13)
Trial: 25609246
Drug: Ganitumab 20
RxNorm normalized name: Ganitumab
DrugBank: Ganitumab (DB12205)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganitumab 20 mg/kg
Trial: 23710586
Drug: Concurrent chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiation (CRT) with cisplatin 40 mg/m² weekly × 5
Trial: 16818817
Drug: ICD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD therapy in NYHA class II
Trial: 16818817
Drug: ICD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD therapy in NYHA class III
Trial: 10760105
Drug: Nutritional parameters
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional parameters (dietary protein intake, energy intake, serum albumin, transferrin, percentage body fat, skinfold thickness, urine creatinine excretion)
Trial: 12631397
Drug: No endocrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No endocrine treatment
Trial: 18555744
Drug: DHA-rich fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-rich fish oil (6 g/day)
Trial: 15533485
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) 2 g three times daily on the day of and the first day after the operation
Trial: 11403540
Drug: H2-receptor antagonists
RxNorm normalized name: H2-receptor antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2-receptor antagonists (cimetidine or ranitidine) or proton pump inhibitors
Trial: 9740281
Drug: Tetracycline (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline (500 mg qid in adults and 12.5 mg/kg qid in children) for 3 days
Trial: 9740281
Drug: Norfloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin (400 mg bid in adults and 7.5 mg/kg bid in children) for 3 days
Trial: 2655906
Drug: Cisapride 5
RxNorm normalized name: cisapride 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 5 mg three times daily for four weeks
Trial: 19772445
Drug: AIR inhaled
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIR inhaled insulin
Trial: 19772451
Drug: AIR inhaled
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIR inhaled insulin plus intensified insulin glargine (AIR + IG)
Trial: 9211437
Drug: d-fenfluramine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-fenfluramine (30 mg p.o.)
Trial: 30985644
Drug: Eplerenone 50
RxNorm normalized name: eplerenone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone 50 mg
Trial: 20219602
Drug: IAN block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IAN block with 1.8 mL of Lidocaine 2% with 1:80,000 epinephrine
Trial: 20219602
Drug: IAN block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IAN block with 3.6 mL of Lidocaine 2% with 1:80,000 epinephrine
Trial: 20219602
Drug: IAN block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IAN block with 1.8 mL and buccal infiltration with 1.8 mL of Lidocaine 2% with 1:80,000 epinephrine
Trial: 12425844
Drug: Local anesthesia
RxNorm normalized name: Esters of benzoic acid for local anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthesia (1.8 ml of 2% lidocaine injected 15 minutes before treatment)
Trial: 10805067
Drug: Problem-based pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-based pharmacotherapy training
Trial: 10805067
Drug: Basic knowledge
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic knowledge about drugs
Trial: 8678631
Drug: Hypothermic CPB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothermic CPB (rectal temperature, 27 degrees C to 28 degrees C)
Trial: 8678631
Drug: Normothermic CPB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normothermic CPB (rectal temperature, more than 35 degrees C)
Trial: 1864299
Drug: Single-dose prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose prophylaxis
Trial: 7060323
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg verapamil intravenously
Trial: 7060323
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg verapamil orally
Trial: 7060323
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg verapamil orally
Trial: 7060323
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg verapamil orally
Trial: 30409780
Drug: Aldosterone levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldosterone levels in response to angiotensin-II infusion
Trial: 25773888
Drug: PhyS-milk (1.57
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PhyS-milk (1.57 g PhyS in 250 ml/day)
Trial: 25773888
Drug: ω3-milk (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω3-milk (375 mg ω3 in 250 ml/day)
Trial: 21569373
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy following the CAPOX treatment scheme
Trial: 8876706
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg finasteride
Trial: 2189187
Drug: Salk killed
RxNorm normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salk killed virus vaccine
Trial: 26908796
Drug: Artemether-Lumefantrine (A-L)
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-Lumefantrine (A-L)
Trial: 10402156
Drug: Spanish version
RxNorm normalized name: Spanish thyme oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spanish version of the 49-item short form of the Addiction Research Center Inventory (ARCI) after administration of sedatives (alcohol, triazolam, flunitrazepam)
Trial: 10402156
Drug: Spanish version
RxNorm normalized name: Spanish thyme oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spanish version of the 49-item short form of the Addiction Research Center Inventory (ARCI) after administration of stimulants (cocaine)
Trial: 10402156
Drug: Spanish version
RxNorm normalized name: Spanish thyme oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spanish version of the 49-item short form of the Addiction Research Center Inventory (ARCI) after administration of opioids (morphine, pentazocine, naloxone)
Trial: 7001898
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment with hydrochlorothiazide, with possible addition of alphamethyldopa or propranolol if needed.
Trial: 7001898
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no drug treatment).
Trial: 7001898
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment group (with diastolic blood pressure >= 100 mm Hg before randomization).
Trial: 31729126
Drug: Blood pressure
RxNorm normalized name: Blood Pressure Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pressure lowering medications
Trial: 21367545
Drug: 16 g
RxNorm normalized name: Maltsupex, 16 g/15 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 g of ethanol daily (females)
Trial: 21367545
Drug: 32 g
RxNorm normalized name: PEG-32 Glyceryl Laurate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 32 g of ethanol daily (males)
Trial: 15023462
Drug: Fast formulation
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast formulation of starch acetate-diltiazem tablets
Trial: 15023462
Drug: Slow formulation
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow formulation of starch acetate-diltiazem tablets
Trial: 7638765
Drug: Continuous force
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous force of 50 cN (approximately 50 g)
Trial: 7638765
Drug: Continuous force
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous force of 100 cN (approximately 100 g)
Trial: 7638765
Drug: Continuous force
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous force of 200 cN (approximately 200 g)
Trial: 2677862
Drug: Intravenous ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ampicillin plus oral erythromycin
Trial: 16583374
Drug: Enzyme replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme replacement therapy (ERT) with 0.2 mg/kg of alpha-galactosidase A (agalsidase-alfa) every 2 weeks for 6 months followed by 12 months of open-label ERT
Trial: 10994682
Drug: Standard Day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Day Treatment Program (DTP)
Trial: 12868995
Drug: OKT3 induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OKT3 induction therapy
Trial: 6085189
Drug: Secretin plus
RxNorm normalized name: Secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Secretin plus Thr28Nle31CCK25‐33 (continuous 6-day intravenous infusion)
Trial: 30409942
Drug: Xylitol chewing
RxNorm normalized name: xylitol Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylitol chewing gums, used thrice daily for 2 weeks
Trial: 9240867
Drug: Zidovudine administration
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine administration to mothers during prenatal and intrapartum periods, and to neonates for 6 weeks
Trial: 2600195
Drug: Diltiazem 30
RxNorm normalized name: diltiazem 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 30 mg
Trial: 3286041
Drug: Diltiazem 30
RxNorm normalized name: diltiazem 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 30 mg plus Nifedipine 10 mg
Trial: 3286041
Drug: Nifedipine 10
RxNorm normalized name: nifedipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 10 mg with Diltiazem
Trial: 11874389
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg meloxicam once
Trial: 11874389
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg ibuprofen three times daily
Trial: 11874389
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg diclofenac SR once
Trial: 8930782
Drug: Befloxatone 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Befloxatone 5 mg
Trial: 8904739
Drug: Befloxatone 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Befloxatone 10 mg
Trial: 8904739
Drug: Befloxatone 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Befloxatone 20 mg
Trial: 1327933
Drug: Low-fiber wheat
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fiber wheat bread (200-300 g/day)
Trial: 3886305
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg alizapride/kg body weight
Trial: 3886305
Drug: 0.6 mg
RxNorm normalized name: thymol 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg domperidone/kg
Trial: 22954674
Drug: Rice containing
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice containing 6.51 g resistant starch daily
Trial: 20082714
Drug: exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: exercise therapy + usual care
Trial: 20591139
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) + usual care
Trial: 12232494
Drug: Fasting (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting (250 kcal; 3 l fluid intake/day) without mineral supplements (n = 103)
Trial: 12232494
Drug: Fasting (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting (250 kcal; 3 l fluid intake/day) with mineral supplements (3 x 2 to 3 x 3 Bullrich's Vital) (n = 106)
Trial: 10421283
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of furosemide therapy
Trial: 1288904
Drug: Ranitidine hydrochloride
RxNorm normalized name: Ranitidine Hydrochloride
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine hydrochloride 2 mg.kg‐1 (Group B)
Trial: 1288904
Drug: Ranitidine liquid
RxNorm normalized name: ranitidine Oral Liquid Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine liquid 2 mg.kg‐1 (Group D)
Trial: 3908214
Drug: Changing-scheme (adriamycin/cisplatinum–vincristine/cyclophosphamide–high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Changing-scheme (adriamycin/cisplatinum–vincristine/cyclophosphamide–high dose methotrexate)
Trial: 27131984
Drug: Two short
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two short implants
Trial: 27131984
Drug: Three short
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three short implants
Trial: 27131984
Drug: Four short
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four short implants
Trial: 22381164
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy in SES stratum (2,735 patients)
Trial: 22381164
Drug: Non-statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-statin therapy in SES stratum (2,294 patients)
Trial: 22381164
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy in BMS stratum (2,576 patients)
Trial: 22381164
Drug: Non-statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-statin therapy in BMS stratum (2,616 patients)
Trial: 20181456
Drug: Well-Being Therapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Well-Being Therapy (WBT)
Trial: 16219435
Drug: Menthol penetration-enhanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menthol penetration-enhanced tetracaine gel (4% tetracaine in carbomer vehicle)
Trial: 16219435
Drug: Non-penetration-enhanced tetracaine
RxNorm normalized name: Tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-penetration-enhanced tetracaine gel (4% tetracaine in carbomer vehicle)
Trial: 12114420
Drug: NSC 655649
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSC 655649 single-dose format (step 1)
Trial: 7595698
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate (HD-MTX) with cranial radiation (CRT)
Trial: 7595698
Drug: Conventional-dose methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Conventional-dose methotrexate (CD-MTX)
Trial: 7595698
Drug: All patients
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients (regardless of treatment)
Trial: 22907764
Drug: Lowest circulating
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lowest circulating CD34(+)KDR(+) in SC rs753482AC+CC
Trial: 19674382
Drug: Algorithm-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algorithm-guided treatment (AGT)
Trial: 11282170
Drug: IFN-beta1a therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IFN-beta1a therapy
Trial: 9041233
Drug: MK-591 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-591 12.5 mg taken twice daily
Trial: 7696378
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg (R,S)‐propranolol.HCl
Trial: 7696378
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg (S)‐propranolol.HCl
Trial: 7696378
Drug: (S)‐propranolol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (S)‐propranolol (20 mg)
Trial: 7696378
Drug: (R)‐propranolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (R)‐propranolol (40 mg)
Trial: 3653122
Drug: Diltiazem (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (25 mg i.v. single dose)
Trial: 28274169
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) 10 mg/kg once a day for the first three days of life plus moderate hypothermia
Trial: 29027817
Drug: 600,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600,000 IU of vitamin D3 (Cholecalciferol) over 10 days in a dose of 60,000 IU/day
Trial: 23690366
Drug: Annexin A5
RxNorm normalized name: Annexin A5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annexin A5 anticoagulant activity
Trial: 23690366
Drug: Children with
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children with SLE and positive anti-DI antibodies
Trial: 15930485
Drug: 1.52 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.52 g/day DHA from capsules containing DHA-rich algal triglycerides
Trial: 6367578
Drug: Probucol and
RxNorm normalized name: Probucol
DrugBank: Probucol (DB01599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Probucol and colestipol combination
Trial: 6367578
Drug: Probucol alone
RxNorm normalized name: Probucol
DrugBank: Probucol (DB01599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Probucol alone or in combination
Trial: 24029016
Drug: 1.5‐s stimulus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5‐s stimulus response (R[L])
Trial: 22551482
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose femoral nerve block (30mL of 0.5% ropivacaine)
Trial: 20660678
Drug: DRV/r 600/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRV/r 600/100 mg BID plus RFB 150 mg QOD
Trial: 20660678
Drug: DRV/r 600/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRV/r 600/100 mg BID
Trial: 10214002
Drug: Group sequential
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group sequential monitoring
Trial: 7043754
Drug: Mianserin 30
RxNorm normalized name: mianserin 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin 30 mg (increased to 60 mg from week 2)
Trial: 11834238
Drug: 6% cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% cellulose sulfate gel (2.5 mL and 5.0 mL doses)
Trial: 11834238
Drug: 6% cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% cellulose sulfate gel (2.5 mL)
Trial: 11834238
Drug: All products
RxNorm normalized name: All Clear Ophthalmic Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All products (6% cellulose sulfate gel, Conceptrol, K-Y jelly)
Trial: 7506854
Drug: PSA values
RxNorm normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA values alone with a cutoff of 10 ng/mL at baseline and 5 ng/mL after twelve months of treatment
Trial: 1167048
Drug: Topical methenamine
RxNorm normalized name: Methenamine
DrugBank: Methenamine (DB06799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical methenamine gel stick
Trial: 31726894
Drug: Intratumoral injection
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intratumoral injection of DNX-2401 followed by surgical resection 14 days later with a second injection into the resection cavity
Trial: 31726894
Drug: DNX-2401 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DNX-2401 treatment